Osteoarthritis (OA) is a common, chronic disease that most frequently affects the knees and is a major cause of disability in the elderly. It is characterized by progressive cartilage loss, accompanied by secondary changes such as osteophyte formation and calcium deposition. Inflammatory processes are also involved, leading to stiffness and pain, for which patients seek treatment. Conventional treatment includes analgesics or non-steroidal antiinflammatory drugs, however life-style changes should also be recommended, such as weight reduction and specific exercises. Glucosamine and chondroitin, classed as over-the-counter supplements or nutraceuticals, are regularly self-administered by patients with OA. Both agents are produced endogenously in the human body and are essential components of cartilage. This review discusses the evidence that supports the use of these agents either alone or in combination for pain relief and as disease-modifying agents in OA.
SpectorTDMacGregorAJ: Epidermiology of rheumatic diseases. In: ABC of Rheumatology, 2nd edn (SnaithML, ed). London: BMJ Books, 1999; pp 82–86.
2.
American College of Rheumatology Subcommittee on Osteoarthritis Guidelines: ACR recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum2000; 43: 1905–1915.
3.
DieppePALohmanderLS: Pathogenesis and management of pain in osteoarthritis. Lancet2005; 365: 965–973.
4.
OwensSWagnerPVangsnessCT: Recent advances in glucosamine and chondroitin supplementation. J Knee Surg2004; 17: 185–193.
5.
LichtensteinDRSyngalSWolfeMM: Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum1995; 38: 5–18.
6.
LozadaCJAltmanRD: Management of limb joint osteoarthritis. Section 11: Osteoarthritis and related disorders. In: Practical Rheumatology, 3rd edn (HochbergMCSilmanAJSmolenJS, eds). Philadelphia: Elsevier (Mosby), 2004; pp 511–519.
7.
SimanekVKrenVUlrichovaJ: The efficacy of glucosamine and chondroitin sulfate in the treatment of osteoarthritis: Are these saccharides drugs or nutraceuticals?Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub2005; 149: 51–56.
8.
BrionPHKalunianKC: Osteoarthritis. Section 18.8. In: Oxford Textbook of Medicine, 4th edn (WarrellDACoxTMFirthJD, eds). London: Oxford University Press, 2004; pp 62–68.
9.
PavelkáKGatterováJOlejarováM: Glucosamine sulfate use and delay of progression of knee osteoarthritis: A 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med2002; 162: 2113–2123.
10.
RichyFBruyereOEthgenO: Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: A comprehensive meta-analysis. Arch Intern Med2003; 163: 1514–1522.
11.
SteinmeyerJKonttinenYT: Oral treatment options for degenerative joint disease–presence and future. Adv Drug Deliv Rev2006; 58: 168–211.
12.
KellyGS: The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Altern Med Rev1998; 3: 27–39.
13.
LippielloLWoodwardJKarpmanR: In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Rel Res2000; 381: 229–240.
14.
DealCLMoskowitzRW: Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am1999; 25: 379–395.
15.
CleggDORedaDJHarrisCL: Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med2006; 354: 795–808.
16.
DasAHammadTA: Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000; 8: 343–350.
17.
DenhamACNewtonWP: Are glucosamine and chondroitin effective in treating osteoarthritis?J Fam Pract2000; 49: 571–572.
18.
LefflerCTPhilippiAFLefflerSG: Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: A randomized, double-blind, placebo-controlled pilot study. Mil Med1999; 164: 85–91.
19.
ShanklandWE: The effects of glucosamine and chondroitin sulfate on osteoarthritis of the TMJ: A preliminary report of 50 patients. Cranio1998; 16: 230–235.
20.
SetnikarIRovatiLC: Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung2001; 51: 699–725.
21.
BarclayTSTsourounisCMcCartGM: Glucosamine. Ann Pharmacother1998; 32: 574–579.
22.
HouptJBMcMillanRWeinC: Effect of glucosamine hydrochloride in the treatment of pain of osteoarthritis of the knee. J Rheumatol1999; 26: 2423–2430.
23.
SetnikarIGiacchettiCZanoloG: Absorption, distribution and excretion of radioactivity after a single intravenous or oral administration of [14C]glucosamine to the rat. Pharmatherapeutica1984; 3: 538–550.
24.
PersianiSRotiniRTrisolinoG: Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulfate at therapeutic dose. Osteoarthritis Cartilage2007; 15: 764–772.
25.
ConteAVolpiNPalmieriL: Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung1995; 45: 918–925.
26.
ConrozierT: Anti-arthrosis treatments: Efficacy and tolerance of chondroitin sulfates (CS 4&6). Presse Med1998; 27: 1863–1865 [in French].
27.
RoncaGConteA: Metabolic fate of partially depolymerized shark chondroitin sulfate in man. Int J Clin Pharmacol Res1993; 13: 27–34.
28.
PalmieriLConteAGiovanniniL: Metabolic fate of exogenous chondroitin sulfate in the experimental animal. Arzneimittelforschung1990; 40: 319–323.
29.
ConteAde BernardiMPalmieriL: Metabolic fate of exogenous chondroitin sulfate in man. Arzneimittelforschung1991; 41: 768–772.
30.
ConteAPalmieriLSegniniD: Metabolic fate of partially depolymerized chondroitin sulfate administered in the rat. Drugs Exp Clin Res1991; 17: 27–33.
31.
BartheLWoodleyJLavitM: In vitro intestinal degradation and adsorption of chondroitin sulfate, a glycosaminoglycan drug. Arzneimittelforschung2004; 54: 286–292.
32.
VolpiN: Oral bioavailability of chondroitin sulfate (Condrosulf®) and its constituents in healthy male volunteers. Osteoarthritis Cartilage2002; 10: 768–777.
ReicheltAForsterKKFischerM: Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. A randomised, placebo-controlled, double-blind study. Arzneimittelforschung1994; 44: 75–80.
35.
Council for Responsible Nutrition (CRN): Glucosamine, chondoitin and joint health. CRN Fact Sheet–Backgounder. Washington: CRN, November 2005, pp 1–10 (available at www.crnusa.org/pdfs/CRN_GlucosamineChondroitin1105.pdf).
36.
NoackWFischerMFörsterKK: Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage1994; 2: 51–59.
37.
RovatiLCGiacovelliGAnnefeldM: A large, randomised, placebo controlled, double-blind study of glucosamine sulfate vs. piroxicam and vs. their association, on the kinetics of the symptomatic effect in knee osteoarthritis. Osteoarthritis Cartilage1994; 2 (suppl 1): 56 [abstract].
38.
Herrero-BeaumontGIvorraJADel CarmenTrabado M: Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum2007; 56: 555–567.
39.
CohenMWolfeRMaiT: A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheumatol2003; 30: 523–528.
40.
BrahamRDawsonBGoodmanC: The effect of glucosamine supplementation on people experiencing regular knee pain. Br J Sports Med2003; 37: 45–49.
41.
HughesRCarrA: A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology (Oxford)2002; 41: 279–284.
42.
RindoneJPHillerDCollacottE: Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med2000; 172: 91–94.
43.
Müller-FassbenderHBachGLHaaseW: Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage1994; 2: 61–69.
44.
QiuGXGaoSNGiacovelliG: Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimittelforschung1998; 48: 469–474.
45.
ThieNMPrasadNGMajorPW: Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: A randomized double blind controlled 3 month clinical trial. J Rheumatol2001; 28: 1347–1355.
46.
LopesVaz A: Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients. Curr Med Res Opin1982; 8: 145–149.
47.
ReginsterJYDeroisyRRovatiLC: Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial. Lancet2001; 357: 251–256.
48.
BruyereOPavelkaKRovatiLC: Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: Evidence from two 3-year studies. Menopause2004; 11: 138–143.
49.
AltmanRDAbadieEAvouacB: Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoporosis. Osteoarthritis Cartilage2005; 13: 13–19.
50.
ChristgauSHenrotinYTankoLB: Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol2004; 22: 36–42.
51.
BourgeoisPChalesGDehaisJ: Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998; 6 (suppl A): 25–30.
52.
BucsiLPoórG: Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage1998; 6 (suppl A): 31–36.
53.
UebelhartDThonarEJDelmasPD: Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: A pilot study. Osteoarthritis Cartilage1998; 6 (suppl A): 39–46.
54.
MazièresBCombeBVan PhanA: Chondroitin sulfate in osteoarthritis of the knee: A prospective, double blind, placebo controlled multicenter clinical study. J Rheumatol2001; 28: 173–181.
55.
UebelhartDMalaiseMMarcolongoR: Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: A one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage2004; 12: 269–276.
56.
MazièresBHucherMZaïmM: Effect of chondroitin sulphate in symptomatic knee osteoarthritis: A multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis2007; 66: 639–645.
57.
MorrealePManopuloRGalatiM: Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol1996; 23: 1385–1391.
58.
VerbruggenGGoemaereSVeysEM: Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol2002; 21: 231–243.
59.
MichelBAStuckiGFreyD: Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: A randomized, controlled trial. Arthritis Rheum2005; 52: 779–786.
60.
PoolsupNSuthisisangCChannarkP: Long-term treatment and the progression of knee osteoarthritis: Systematic review of randomized controlled trials. Ann Pharmacother2005; 39: 1080–1087.
61.
AdebowaleAOCoxDSLiangZ: Analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials. JANA2000; 3: 37–44.
62.
Danao-CamaraT: Potential side effects of treatment with glucosamine and chondroitin. Arthritis Rheum2000; 43: 2853.
63.
MatheuVGraciaBara MTPeltaR: Immediate-hypersensitivity reaction to glucosamine sulfate. Allergy1999; 54: 643.
64.
TalliaAFCardoneDA: Asthma exacerbation associated with glucosamine–chondroitin supplement. J Am Board Fam Pract2002; 15: 481–484.
65.
TapadinhasMJRiveraICBignaminiAA: Oral glucosamine sulphate in the management of arthrosis: Report on a multi-centre open investigation in Portugal. Pharmatherapeutica1982; 3: 157–168.
66.
AndersonJWNicolosiRJBorzellecaJF: Glucosamine effects in humans: A review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol2004; 43: 187–201.
67.
TannisAJBarbanJConquerJA: Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthritis Cartilage2004; 12: 506–511.
68.
ScroggieDAAlbrightAHarrisMD: The effect of glucosamine–chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: A placebo-controlled, double-blinded, randomized clinical trial. Arch Intern Med2003; 163: 1587–1590.
69.
QiuGXWengXSZhangK: A multi-central, randomized, controlled clinical trial of glucosamine hydrochloride/sulfate in the treatment of knee osteoarthritis. Zhonghua Yi Xue Za Zhi2005; 85: 3067–3070.
70.
HofferLJKaplanLNHamadehMJ: Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism2001; 50: 767–770.
71.
Vidal y PlanaRRBizzarriDRovatiAL: Articular cartilage pharmacology: I. In vitro studies on glucosamine and non steroidal antiinflammatory drugs. Pharmacol Res Commun1978; 10: 557–569.
72.
SetnikarIPalumboRCanaliS: Pharmacokinetics of glucosamine in man. Arzneimittelforschung1993; 43: 1109–1113.
73.
Läkemedelsverket: Information från Läkemedelsverket nr 4, 2007 [Swedish Medical Products Agency: Information from the Medical Products Agency, number 4, Uppsala: Swedish Medical Products Agency, 2007].
74.
JordanKMArdenNKDohertyM: EULAR Recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis2003; 62: 1145–1155.
